Systolic blood pressure and albuminuria reduction mediate cardiovascular benefits of finerenone in T2 diabetes and CKD
Abstract
Background and hypothesis Finerenone reduces cardiovascular events in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The cardiovascular benefit emerges within months, before measurable kidney protection, but the early pathways carrying it are not comprehensively quantified. We hypothesized that early reductions in urine albumin-to-creatinine ratio (UACR) and systolic blood pressure (SBP) jointly mediate a substantial proportion of finerenone’s long-term cardiovascular benefit, whereas changes in body weight and serum potassium do not. Methods We performed causal mediation analysis using individual patient data from FIDELITY (pooled FIDELIO-DKD and FIGARO-DKD; n = 12,143). Mediators were change from baseline to month 4 in log UACR, SBP, body weight, and serum potassium. The outcome was time from month 4 to first cardiovascular event (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure hospitalization). Outcome models used parametric accelerated failure time regression with Weibull distribution. Joint mediation by UACR and SBP was estimated by bootstrapping. Results At month 4, finerenone reduced UACR by 32.2% (95% CI 30.3 to 34.2), SBP by 3.6 mmHg (3.1 to 4.1), and body weight by 0.23 kg (0.13 to 0.32), and increased serum potassium by 0.19 mEq/l (0.17 to 0.20). Although all four biomarkers changed significantly, only UACR and SBP mediated cardiovascular outcomes: UACR mediated 39% (95% CI 7 to 71) and SBP mediated 21% (3 to 40); body weight and potassium did not. Jointly, UACR and SBP mediated 50% (95% CI 21 to 100) of the cardiovascular benefit. Conclusions In T2D and CKD, early reductions in UACR and SBP jointly account for half of finerenone’s long-term cardiovascular benefit. Body weight and potassium changes do not mediate the benefit, supporting UACR and SBP as complementary indicators of cardiovascular efficacy.
Related
- Whole-Blood Transcriptomics Highlights Galectin-1 in Systolic Blood Pressure
- Adjusting for Medication Use in GWAS and Its Impact on Mendelian Randomisation Analyses: An Example of Systolic Blood Pressure in UK Biobank
- Associations of the metabolic score for insulin resistance and uric acid with prevalent thyroid nodules: A cross-sectional study with systolic blood pressure mediation analysis and C-TIRADS category-specific analyses
- Heterogeneous cardiovascular responses to acute mean arterial pressure augmentation in septic shock: the role of ventriculo-arterial coupling and venous return
- Carboxysome-Inspired Protein Coacervates for Light-Driven CO2 Reduction and H2 Evolution
BibTeX
@article{agarwal2026systolic,
title = {{Systolic blood pressure and albuminuria reduction mediate cardiovascular benefits of finerenone in T2 diabetes and CKD}},
author = {Rajiv Agarwal and Ambarish Pandey and Scott D Solomon and Muthiah Vaduganathan and Faiez Zannad},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
month = jun,
doi = {10.1093/ndt/gfag150},
url = {https://hal.univ-lorraine.fr/hal-05759399v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Systolic blood pressure and albuminuria reduction mediate cardiovascular benefits of finerenone in T2 diabetes and CKD
AU - Rajiv Agarwal
AU - Ambarish Pandey
AU - Scott D Solomon
AU - Muthiah Vaduganathan
AU - Faiez Zannad
PY - 2026
DA - 2026/06/26
JO - Nephrology Dialysis Transplantation
DO - 10.1093/ndt/gfag150
UR - https://hal.univ-lorraine.fr/hal-05759399v1
AB - Background and hypothesis Finerenone reduces cardiovascular events in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The cardiovascular benefit emerges within months, before measurable kidney protection, but the early pathways carrying it are not comprehensively quantified. We hypothesized that early reductions in urine albumin-to-creatinine ratio (UACR) and systolic blood pressure (SBP) jointly mediate a substantial proportion of finerenone’s long-term cardiovascular benefit, whereas changes in body weight and serum potassium do not. Methods We performed causal mediation analysis using individual patient data from FIDELITY (pooled FIDELIO-DKD and FIGARO-DKD; n = 12,143). Mediators were change from baseline to month 4 in log UACR, SBP, body weight, and serum potassium. The outcome was time from month 4 to first cardiovascular event (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure hospitalization). Outcome models used parametric accelerated failure time regression with Weibull distribution. Joint mediation by UACR and SBP was estimated by bootstrapping. Results At month 4, finerenone reduced UACR by 32.2% (95% CI 30.3 to 34.2), SBP by 3.6 mmHg (3.1 to 4.1), and body weight by 0.23 kg (0.13 to 0.32), and increased serum potassium by 0.19 mEq/l (0.17 to 0.20). Although all four biomarkers changed significantly, only UACR and SBP mediated cardiovascular outcomes: UACR mediated 39% (95% CI 7 to 71) and SBP mediated 21% (3 to 40); body weight and potassium did not. Jointly, UACR and SBP mediated 50% (95% CI 21 to 100) of the cardiovascular benefit. Conclusions In T2D and CKD, early reductions in UACR and SBP jointly account for half of finerenone’s long-term cardiovascular benefit. Body weight and potassium changes do not mediate the benefit, supporting UACR and SBP as complementary indicators of cardiovascular efficacy.
SN - 0931-0509
SN - 1460-2385
ER -